PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product Chemotherapy - Market size and forecast 2018-2023 Other therapeutics - Market size and forecast 2018-2023 Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Increasing awareness of malignant mesothelioma Development of novel therapies Reimbursement policies for chemotherapy PART 12: VENDOR LANDSCAPE Overview Landscape disruption PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Bristol-Myers Squibb Co. Eli Lilly and Co. F. Hoffmann-La Roche Ltd. Merck & Co. Inc. Pfizer Inc. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global oncology therapeutics market Exhibit 02: Segments of global oncology therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Product - Market share 2018-2023 (%) Exhibit 18: Comparison by product Exhibit 19: Chemotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Chemotherapy - Year-over-year growth 2019-2023 (%) Exhibit 21: Other therapeutics - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Other therapeutics - Year-over-year growth 2019-2023 (%) Exhibit 23: Market opportunity by product Exhibit 24: Customer landscape Exhibit 25: Market share by geography 2018-2023 (%) Exhibit 26: Geographic comparison Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 28: North America - Year-over-year growth 2019-2023 (%) Exhibit 29: Top 3 countries in North America Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 31: Europe - Year-over-year growth 2019-2023 (%) Exhibit 32: Top 3 countries in Europe Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Asia - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in Asia Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 37: ROW - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in ROW Exhibit 39: Key leading countries Exhibit 40: Market opportunity Exhibit 41: Drug designations Exhibit 42: Impact of drivers and challenges Exhibit 43: Vendor landscape Exhibit 44: Landscape disruption Exhibit 45: Vendors covered Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: Bristol-Myers Squibb Co. - Vendor overview Exhibit 49: Bristol-Myers Squibb Co. - Product segments Exhibit 50: Bristol-Myers Squibb Co. - Organizational developments Exhibit 51: Bristol-Myers Squibb Co. - Geographic focus Exhibit 52: Bristol-Myers Squibb Co. - Key offerings Exhibit 53: Bristol-Myers Squibb Co. - Key customers Exhibit 54: Eli Lilly and Co. - Vendor overview Exhibit 55: Eli Lilly and Co. - Business segments Exhibit 56: Eli Lilly and Co. - Organizational developments Exhibit 57: Eli Lilly and Co. - Geographic focus Exhibit 58: Eli Lilly and Co. - Segment focus Exhibit 59: Eli Lilly and Co. - Key offerings Exhibit 60: Eli Lilly and Co. - Key customers Exhibit 61: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 62: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 63: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 64: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 65: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 66: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 67: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 68: Merck & Co. Inc. - Vendor overview Exhibit 69: Merck & Co. Inc. - Business segments Exhibit 70: Merck & Co. Inc. - Organizational developments Exhibit 71: Merck & Co. Inc. - Geographic focus Exhibit 72: Merck & Co. Inc. - Segment focus Exhibit 73: Merck & Co. Inc. - Key offerings Exhibit 74: Merck & Co. Inc. - Key customers Exhibit 75: Pfizer Inc. - Vendor overview Exhibit 76: Pfizer Inc. - Business segments Exhibit 77: Pfizer Inc. - Organizational developments Exhibit 78: Pfizer Inc. - Geographic focus Exhibit 79: Pfizer Inc. - Segment focus Exhibit 80: Pfizer Inc. - Key offerings Exhibit 81: Pfizer Inc. - Key customers Exhibit 82: Validation techniques employed for market sizing Exhibit 83: Definition of market positioning of vendors

Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., and Pfizer Inc.